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The commercially available steroid dehydroepiandrosterone
3-acetate (DHEA) was converted into new, highly function-
alized spiro derivatives by modification of the D-ring. The
transformation proceeded through conversion of the C-17
carbonyl group into an electron-deficient alkene, followed by
either [2+2] or [4+2] cycloaddition. The cycloaddition reac-
Introduction
The modification of natural products to discover new
drugs remains an important area of research.[1] In this ap-
proach, the natural product (or part of it) is used as a privi-
leged template for recognition by receptor molecules, while
the modification can lead to improved or entirely new bio-
activity.[2] Among the surfeit of bioactive natural products,
steroids are an attractive starting point. Numerous existing
drugs are steroidal derivatives that exert a wide variety of
biological activities, such as agonistic or antagonistic effects
on estrogen, androgen, progestin and corticoid receptors,
and inhibition of steroidogenic enzymes.[3] A plethora of
interesting examples of steroid modification have been re-
ported,[1c,4] such as the conversion of cholic acid into an
orthogonally protected triamino steroid,[5] and the copper-
catalyzed cyclization of steroidal acylaminoacetylenes.[6]
The latter spiro products showed an improved ratio of anti-
progestational over antiglucocorticoid activity as compared
to its acyclic counterpart mifepristone.[7]
In previous research, we developed a straightforward ap-
proach to the synthesis of compound libraries containing
conformationally restrained arylethylamine moieties,[8]
which are privileged elements in drugs acting on the central
nervous system. In this work, we aimed to apply this newly
developed methodology to steroids. Acetyl-protected de-
hydroepiandrosterone (1, DHEA), a biologically active,[9]
commercially available steroid containing a C-17 ketone
functionality, was chosen as the starting material. The
steroid structure acts as a biological directing group for pro-
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tions were successful for alkylidene malononitriles and 2-cy-
ano acrylates. Application of high pressure (15 kbar) was es-
sential for good conversions due to the high steric hindrance
on position C-17. The cycloadducts formed from the reaction
of 2-cyano acrylates and Danishefsky’s diene have high po-
tential for further functionalization.
tein-binding ligands, while derivatization of the ketone at C-
17 may act as a trigger for new activity. Retrosynthetically,
starting from the anticipated steroid derivatives 4, the
amino group could be derived from compounds 3, pos-
sessing a masked amino function such as nitro and cyano,
by reduction. Cycloaddition should take place to generate
these compounds from the corresponding electron-deficient
alkenes 2, which, in turn, could be derived from DHEA (1)
through Knoevenagel condensation with active methylene
compounds (Scheme 1).
Scheme 1. Sequence of reactions for derivatizing bioactive com-
pounds.
At the outset of our synthetic attempts it was recognized
that steric hindrance from the C-ring and the methyl group
(C-18) at the C–D ring junction impose a reduction of reac-
tivity of electron-deficient alkenes derived from DHEA.
However, knowing that high pressure can overcome steric
hindrance,[10] we were prompted by the synthetic challenge
to functionalize the D-ring of DHEA through a high-pres-
sure-promoted cycloaddition reaction.
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Results and Discussion
Synthesis of the DHEA derivatives commenced with
Knoevenagel condensation[11] of an active methylene com-
pound and DHEA (1). Treatment of compound 1 with ma-
lononitrile or methyl 2-cyanoacetate with ammonium acet-
ate as catalyst in a mixture of acetic acid/toluene gave tetra-
substituted alkenes 5 and 6, respectively, in high yields
(Scheme 2). The Knoevenagel reaction of methyl 2-cyano-
acetate is known to selectively form the major products hav-
ing the nitrile cis with respect to the bulkier group of the
original ketone.[12] In this case, only the isomers depicted in
Scheme 2 were formed. The reaction was also performed
with methyl 2-nitroacetate, but once the corresponding
product was formed, the alkene isomerized to the β,γ-posi-
tion, probably due to steric congestion of the tetrasubsti-
tuted alkene.[13] The unsuitability of the latter product for
the intended cycloaddition reactions led us to abandon the
use of nitroacetates.
Scheme 2. Knoevenagel condensation of DHEA (1) and subse-
quent [2+2] cycloaddition.
Cyano acrylic derivatives 5 and 6 were used to explore
[2+2] and [4+2] cycloaddition reactions towards new steroid
derivatives with a more complex hydrocarbon framework.
Initial studies on cycloaddition reactions of electron-de-
ficient alkenes 5 and 6 showed that only doubly activated
alkenes and dienes under high-pressure conditions yielded
cycloadducts. The reactions of compounds 5 and 6 with
ethoxyethene and tert-butoxyethene were unsuccessful.
However, when 5 and 6 were treated with more electron-
rich olefins 1,1-dimethoxyethene (in benzene) and 1,1-di-
methoxyprop-1-ene (in chloroform) under 15 kbar pressure,
products 7–12 were formed (Scheme 2). Most likely, the for-
mation of these cyclobutanes proceeds in a stepwise manner
via a zwitterionic intermediate.[14] The formation of cyclo-
butanes 7–10 can be explained by reaction of the electron-
rich alkene from the bottom face of electron-deficient alk-
enes 5 and 6 (because of the β-methyl group on C-13),[15]
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with the R group approaching away from the steroid
(Scheme 3). That is, the formation of the first C–C bond is
completely diastereoselective and takes place from the Re
face of C-2 in the case of 1,1-dimethoxyprop-1-ene. The
zwitterionic intermediate can rotate through C-17–C-20
and then cyclize on either face of the anion, forming prod-
ucts 7–10. This reaction sequence would explain the forma-
tion of a single product and two products in the case of Y
= CN and CO2Me, respectively, when 1,1-dimethoxyprop-
1-ene was used.[16] The cycloadducts 7 and 8 partially hy-
drolyzed to the open products 13 and 14a,b during purifica-
tion by silica gel column chromatography. In this manner,
the crude cycloaddition mixtures were treated directly with
1 n HCl to give full conversion of the hydrolyzed products
13 and an inseparable mixture of compounds 14a and 14b
(2.7:1.0).[17] Compounds 9 and 10a,b were purified by col-
umn chromatography without partial hydrolysis. Interest-
ingly, these compounds were also unreactive to concen-
trated HCl.[18]
Scheme 3. Reaction sequence for the formation of products 7–10.
On the other hand, the formation of products 11 and 12
could be explained by an ene reaction of 1,1-dimeth-
oxyprop-1-ene and the β,γ-unsaturated isomers of 5 and 6.
Traces of HCl present in chloroform could probably aid in
the isomerization of 5 and 6. The stereochemistry at C-16 of
products 11 and 12 was confirmed by NOESY experiments.
To successfully perform the [4+2] cycloaddition reac-
tions, doubly activated dienes were required. The reactions
of compounds 5 and 6 with 2,3-dimethylbuta-1,3-diene and
2-methoxybuta-1,3-diene resulted in no observable cycload-
ducts. Nevertheless, the Diels–Alder reaction of 1-methoxy-
3-[(trimethylsilyl)oxy]buta-1,3-diene (Danishefsky’s diene)
and electron-deficient alkenes 5 and 6 in dichloromethane
under a 15 kbar pressure yielded cycloadducts 15a,b and
16a,b, respectively, after aqueous hydrolysis (Scheme 4). In
both cases, a mixture of two isomers was obtained (out of
the four possible stereoisomers: endo/exo and top/bottom
approaches). The major isomer was formed by reaction of
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Scheme 4. High-pressure Diels–Alder reaction of cyano acrylic derivatives 5 and 6 with Danishesfky’s diene.
the diene from the bottom face of compounds 5 and 6 (this
statement was confirmed by a NOESY NMR experiment
performed with the final product 20; see the Supporting
Information) approaching away from the steroid (endo ap-
proach of Y) as depicted in Scheme 5. Thus, the major iso-
mer presents the methoxy group cis with respect to the Y
group (CN or CO2Me).
Scheme 5. Major approach for the [4+2] cycloaddition of com-
pounds 5 and 6 and the Danishesfky’s diene.
The stereochemistry of the products was confirmed by
NMR spectroscopy. The major products of both reactions,
compounds 15a and 16a, presented a triplet (J = 4.1 Hz
and J = 6.4 Hz, respectively) in the 1H NMR spectra, as-
signed to the signals of the protons on C-3. The minor
products, compounds 15b and 16b on the other hand, pre-
sented a doublet of doublets (J = 11.9, 5.0 Hz in both cases)
for the same protons. This can be explained by the preferen-
tial conformation that compounds 15a and 16a adopt
(Scheme 6).[19]
Scheme 6. Conformational analysis of cycloadducts 15a and 16a.
Due to the higher chemical versatility of esters compared
to nitriles, it was decided to proceed with compound 16 for
further functional group modification in the quest for new,
highly functionalized steroids. In this way, the sacrificial
methyl ester required for the cycloadditions to take place
was eliminated by reaction with lithium methoxide in meth-
anol. Thus, compound 16a gave rise to dienecarbonitrile 17
and keto nitrile 18 in good yields (Scheme 7) depending on
the procedure used for quenching the reaction mixture (acet-
ic anhydride in pyridine or aqueous work-up, respectively).
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The elimination reaction of CO2Me and OMe may follow
an E1cB mechanism with CO2Me as the electrofuge (this
could be considered a retro-Claisen condensation) and
OMe as the nucleofuge.[20]
Scheme 7. Derivatization of compound 16a.
Keto nitrile 18 was further derivatized to the protected
amino ketone 20 (Scheme 7). Reduction of the less hindered
alkene (without purification of compound 18 from 16a)
with a palladium catalyst under a hydrogen atmosphere af-
forded keto nitrile 19 stereospecifically. Reduction of the
nitrile to the primary amine was accomplished with LiAlH4
in tetrahydrofuran (THF) with previous protection of the
ketone under standard conditions. Thus, keto nitrile 19 re-
acted with trimethyl orthoformate in methanol with cata-
lytic sulfuric acid to yield the protected ketone as a dimethyl
acetal. Subsequent reduction of the nitrile, followed by acet-
ylation (Ac2O, pyridine) and deprotection of the ketone af-
forded the protected amino ketone 20. The latter is a steroid
derivative with potential activity in any of the roles of de-
hydroepiandrosterone. Furthermore, compound 20 presents
four important functional groups that could be used for
further derivatization and are hence amenable to combina-
torial functionalization.
Extension of the Privileged Steroid Scaffold
Conclusions
In summary, the synthesis of new steroid derivatives with
complex hydrocarbon frameworks is presented. We have de-
veloped an efficient method for the derivatization of C-17
of dehydroepiandrosterone 3-acetate by a Knoevenagel con-
densation followed by [2+2] or [4+2] cycloaddition. This
derivatization includes the formation of a new cycle in a
spiro fashion and, in the case of the [4+2] cycloaddition,
eventually yields a highly functionalized steroid derivative
that could be further derivatized.
Experimental Section
General Methods: Commercially available chemicals were used
without purification. Solvents were distilled from appropriate dry-
ing agents prior to use and stored under nitrogen. Reactions were
followed, and RF values were obtained, by using thin-layer
chromatography (TLC) on silica gel-coated plates (Merck 60 F254).
Detection was performed with UV light and by charring at
ca. 150 °C after dipping the TLC plate into a basic aqueous solu-
tion of KMnO4. Column or flash chromatography was carried out
using ACROS silica gel (0.035–0.070 mm, pore diameter ca. 6 nm).
NMR spectra were recorded with a Bruker DMX 300 (300 MHz)
or a Varian 400 (400 MHz) spectrometer in CDCl3 solutions.
Chemical shifts are given in parts per million (ppm) with respect
to tetramethylsilane (TMS) as internal standard. Coupling con-
stants are reported as J values in Hertz (Hz). Elemental analyses
were carried out with a Carlo Erba Instruments CHNS-O EA 1108
element analyzer. Low-resolution mass spectra were recorded with
a MAT900 (EI and FAB). Melting points were measured with a
Reichert Thermopan microscope. IR spectra were recorded with a
Bruker Tensor 27 FTIR spectrometer.
(3S)-17-(Dicyanomethylidene)androst-5-en-3-yl Acetate (5): A
round-bottomed flask fitted with a Dean–Stark apparatus, a reflux
condenser, and a drying tube containing calcium chloride was
charged with a solution of DHEA (1; 4.00 g, 12.12 mmol),
CH2(CN)2 (1.60 g, 24.24 mmol), and NH4OAc (1.87 g,
24.24 mmol) in AcOH (16 mL) and toluene (60 mL). The resulting
mixture was stirred and heated to reflux for 48 h, then concentrated
in vacuo. The residue of the reaction was dissolved in CH2Cl2 and
washed sequentially with 0.5 n KHSO4 and a saturated solution
of NaHCO3. The organic layer was dried (Na2SO4), filtered, and
concentrated in vacuo. Purification by column chromatography on
silica gel (heptane/EtOAc, 7:3) gave 5 (3.81 g, 10.06 mmol, 83%),
m.p. 190–191 °C (iPr2O). 1H NMR (300 MHz, CDCl3): δ = 5.38
(d, J = 5.1 Hz, 1 H, 6-H), 4.66–4.54 (m, 1 H, 3-H), 3.00–2.87 (m,
1 H, 16-H), 2.80–2.64 (m, 1 H, 16-H), 2.55–2.41 (m, 1 H), 2.41–
2.24 (m, 2 H), 2.15–2.00 (m, 1 H), 2.04 (s, 3 H, CH3CO), 1.97–
0.97 (m, 16 H), 1.05 (s, 6 H, 18-CH3 and 19-CH3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 195.6 (17-C), 170.0 (CO2), 139.6 (5-C), 121.3
(6-C), 112.0 (CN), 111.0 (CN), 79.6 [=C(CN)2], 73.5 (3-C), 55.2
(14-C), 49.4, 48.9, 38.1, 36.9, 36.6, 34.8, 37.0, 31.49, 31.46, 27.7,
23.7, 21.5, 20.9, 19.4 (19-C), 16.4 (18-C) ppm. C24H30N2O2
(378.51): calcd. C 76.16, H 7.99, N 7.40; found C 76.34, H 7.88, N
7.26. MS (FAB+): m/z (%) = 379 (2) [M + 1]+, 319 (79) [M –
AcO]+.
Methyl (E)-2-[(3S)-3-Acetoxyandrost-5-en-17-ylidene]-2-cyanoacet-
ate (6): A round-bottomed flask fitted with a Dean–Stark appara-
tus, a reflux condenser, and a drying tube containing calcium chlor-
ide, was charged with a solution of DHEA (1; 2.42 g, 7.33 mmol),
NCCH2CO2Me (1.46 g, 11.50 mmol), and NH4OAc (1.14 g,
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14.79 mmol) in AcOH (10 mL) and toluene (40 mL). The resulting
reaction mixture was stirred and heated to reflux for 48 h, then
concentrated in vacuo. The residue of the reaction was dissolved in
CH2Cl2 and washed sequentially with 0.5 n KHSO4 and a satu-
rated solution of NaHCO3. The organic layer was dried (Na2SO4),
filtered, and concentrated in vacuo. Purification by column
chromatography on silica gel (heptane/EtOAc, 2:1) gave 6 (2.83 g,
6.87 mmol, 94%). 1H NMR (300 MHz, CDCl3): δ = 5.39 (d, J =
4.8 Hz, 1 H, 6-H), 4.67–4.54 (m, 1 H, 3-H), 3.81 (s, 3 H, OCH3),
3.24–3.10 (m, 1 H), 3.01–2.76 (m, 2 H), 2.41–2.24 (m, 2 H), 2.15–
1.99 (m, 1 H), 2.04 (s, 3 H, CH3CO), 1.94–1.81 (m, 3 H), 1.80–1.44
(m, 6 H), 1.42–0.97 (m, 4 H), 1.05 (s, 3 H, CH3), 1.03 (s, 3 H,
CH3) ppm. 13C NMR (75 MHz, CDCl3): δ = 192.2 (17-C), 170.5
(CO2), 163.1 (CO2), 139.9 (5-C), 121.8 (6 C), 115.0 (CN), 98.3
(=CCN), 73.7 (3-C), 54.8, 52.4, 49.5, 48.8, 38.0, 36.8, 36.5, 34.8,
34.0, 31.6, 31.3, 27.6, 23.9, 21.4, 21.0, 19.2 (19-C), 15.8 (18-C) ppm.
C25H33NO4 (411.54): calcd. C 72.96, H 8.08, N 3.40; found C
72.98, H 8.21, N 3.54.
(3S,4S,17R)-2,2-Dicyano-3,3-dimethoxy-4-methylspiro[an-
drostane-17,1-cyclobutan]-5-en-3-yl Acetate (9) and (3S,16R)-17-
(Dicyanomethylidene)-16-(1,1-dimethoxypropyl)androst-5-en-3-yl
Acetate (11): A flexible 7.5 mL PTFE tube was charged with 5
(900 mg, 2.38 mmol), 1,1-dimethoxyprop-1-ene (720 mg,
7.06 mmol), and enough CHCl3 to fill the tube up. The reaction
mixture was set at 15 kbar and 50 °C for 72 h. After this time, the
reaction mixture was concentrated in vacuo and heptane was added
to the residue. After vigorous stirring, crystals were formed, which
were collected by filtration. Further purification of the crystals by
column chromatography on silica gel (heptane/EtOAc, 9:1) gave 9
(425 mg, 0.88 mmol, 37%) and 11 (235 mg, 0.49 mmol, 21%).
Compound 9: M.p. 177–178 °C. 1H NMR (300 MHz, CDCl3): δ =
5.35 (d, J = 4.3 Hz, 1 H, 6-H), 4.65–4.52 (m, 1 H, 3-H), 3.49 (s, 3
H, OCH3), 3.36 (s, 3 H, OCH3), 2.98 (q, J = 7.0 Hz, 1 H, 4-H),
2.36–2.06 (m, 5 H), 2.03 (s, 3 H, CH3CO), 2.04–1.92 (m, 1 H),
1.92–1.80 (m, 2 H), 1.72–1.44 (m, 6 H), 1.40–1.23 (m, 2 H), 1.10
(d, J = 7.0 Hz, 3 H, 4-CH3), 1.19–0.87 (m, 3 H), 1.03 (s, 3 H,
CH3), 0.99 (s, 3 H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ =
170.2 (CO2), 139.6 (5-C), 121.7 (6-C), 113.6 (CN), 112.6 (CN),
100.5 (OCO), 73.8 (3-C), 54.7, 54.0, 51.4, 51.2, 49.7, 46.1, 43.4,
42.6, 38.2, 37.1, 36.7, 32.9, 32.7, 31.9, 28.3, 27.8, 23.9, 21.6, 20.7,
19.5 (19-C), 14.1 (18-C), 11.7 (4-CH3) ppm. C29H40N2O4 (480.65):
calcd. C 72.47, H 8.39, N 5.83; found C 72.36, H 8.44, N 5.65. MS
(FAB+): m/z (%) = 481 (8) [M + 1]+, 449 (14) [M – MeO]+, 421
(9) [M – AcO]+, 389 (6) [M – MeOH – AcO]+.
Compound 11: M.p. 173–174 °C. 1H NMR (300 MHz, CDCl3): δ =
5.38 (d, J = 5.4 Hz, 1 H, 6-H), 4.65–4.52 (m, 1 H, 3-H), 3.42 (d, J
= 8.1 Hz, 1 H, 16-H), 3.21 (s, 3 H, OCH3), 3.16 (s, 3 H, OCH3),
2.79–2.74 (m, 1 H), 2.40–2.24 (m, 2 H), 2.11–2.03 (m, 1 H), 2.03
(s, 3 H, CH3CO), 1.94–1.79 (m, 3 H), 1.79–1.38 (m, 10 H), 1.20–
1.02 (m, 2 H), 1.11 (s, 3 H, CH3), 1.03 (s, 3 H, CH3), 0.81 (t, J =
7.5 Hz, 3 H, CH2CH3), ppm. 13C NMR (75 MHz, CDCl3): δ =
193.4 (17-C), 170.5 (CO2), 140.0 (5-C), 121.6 (6-C), 113.6 (CN),
112.9 (CN), 106.1 (OCO), 83.5 [=C(CN)2], 73.6 (3-C), 53.0, 50.7,
50.6, 49.5, 48.3, 48.5, 38.0, 36.8, 36.6, 34.1, 31.6, 31.1, 27.6, 27.5,
21.4, 20.9, 19.2, 19.0, 9.0 (CH2CH3) ppm.
Methyl (2S,3S,4S,17R)-3-Acetoxy-2-cyano-3,3-dimethoxy-4-
methylspiro[androstane-17,1-cyclobutan]-5-ene-2-carboxylate
(10a), Methyl (2R,3S,4S,17R)-3-Acetoxy-2-cyano-3,3-dimeth-
oxy-4-methylspiro[androstane-17,1-cyclobutan]-5-ene-2-carb-
oxylate (10b) and Methyl (E)-2-[(3S,16R)-3-Acetoxy-16-(1,1-di-
methoxypropyl)androst-5-en-17-ylidene]-2-cyanoacetate (12): A flex-
ible 7.5 mL PTFE tube was charged with compound 6 (750 mg,
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1.82 mmol), 1,1-dimethoxyprop-1-ene (400 mg, 3.92 mmol), and
enough CHCl3 to fill the tube up. The reaction mixture was set at
15 kbar and 50 °C for 96 h. After this time, the reaction mixture
was concentrated in vacuo and the residue was purified by column
chromatography on silica gel (heptane/EtOAc, 5:1) to give a 4.0:1.0
mixture of compounds 10a and 10b (173 mg, 0.34 mmol, 18%), and
compound 12 (236 mg, 0.46 mmol, 25%).
Compounds 10a and 10b: 1H NMR (300 MHz, CDCl3): δ = 5.36–
5.31 (m, 1 H, 6-H), 4.64–4.51 (m, 1 H, 3-H), 3.79 and 3.77 (2 s,
3 H, OCH3), 3.46 and 3.32 (2 s, 3 H, OCH3), 3.40 and 2.82 (2q,
J = 6.9 and 7.2 Hz, 1 H, 4-H), 3.20 and 3.18 (2 s, 3 H, OCH3),
2.33–2.20 (m, 4 H), 2.10–1.92 (m, 2 H), 2.01 (s, 3 H, CH3CO),
1.92–1.80 (m, 2 H), 1.68–0.80 (m, 14 H), 0.98 (s, 3 H, 19-CH3), 0.99
and 0.69 (2 s, 3 H, 18-CH3) ppm. 13C NMR (75 MHz, CDCl3): δ
= 170.5 (CO2), 165.8 (CO2), 165.2 (CO2), 139.8 (5-C), 139.7 (5-C),
122.2 (6-C), 122.1 (6-C), 117.4 (CN), 116.6 (CN), 101.2 (OCO),
100.4 (OCO), 73.8 (3-C), 59.2, 56.0, 55.0, 53.0, 52.8, 52.3, 50.9,
50.6, 49.6, 45.8, 41.6, 38.0, 36.9, 36.53, 36.46, 33.9, 32.6, 32.5, 31.8,
30.0, 27.7, 23.9, 23.7, 21.4, 20.9, 20.7, 19.2 (19-C), 14.4 (18-C), 11.5
(4-CH3), 11.4 (4-CH3) ppm.
Compound 12: 1H NMR (400 MHz, CDCl3): δ = 5.40–5.36 (m, 1
H, 6-H), 4.64–4.53 (m, 1 H, 3-H), 3.92 (d, J = 8.3 Hz, 1 H, 16-H),
3.79 (s, 3 H, OCH3), 3.12 (s, 3 H, OCH3), 3.08 (s, 3 H, OCH3),
2.82–2.78 (m, 1 H), 2.40–2.25 (m, 2 H), 2.11–2.03 (m, 1 H), 2.04
(s, 3 H, CH3CO), 1.94–1.79 (m, 3 H), 1.79–1.38 (m, 10 H), 1.20–
1.02 (m, 2 H), 1.09 (s, 3 H, CH3), 1.05 (s, 3 H, CH3), 0.80 (t, J =
7.6 Hz, 3 H, CH2CH3) ppm.
Methyl 2-[(3S,17S)-3-Acetoxy-17-(dicyanomethyl)androst-5-en-17-
yl]acetate (13): A flexible 7.5 mL PTFE tube was charged with 5
(500 mg, 1.32 mmol), 1,1-dimethoxyethene (300 mg, 3.40 mmol),
and enough benzene to fill the tube up. The reaction mixture was
set at 15 kbar and 50 °C for 16 h. After this time, the reaction mix-
ture was concentrated in vacuo and the residue was dissolved in
THF (20 mL) and 10% HCl (6 mL) was added. The reaction mix-
ture was stirred at room temperature for 30 min and then THF was
removed under reduced pressure. The resulting aqueous solution
was extracted with CH2Cl2 and the combined organic layers were
dried (Na2SO4), filtered, and concentrated in vacuo. Purification
by column chromatography on silica gel (heptane/EtOAc, 5:1) gave
13 (510 mg, 1.13 mmol, 85%), m.p. 201–204 °C (heptane/EtOAc,
1:1). 1H NMR (300 MHz, CDCl3): δ = 5.37 (d, J = 5.1 Hz, 1 H,
6-H), 4.87 [s, 1 H, CH(CN2)], 4.66–4.53 (m, 1 H, 3-H), 3.74 (s, 3
H, OCH3), 2.65 (ABq, ΔδAB = 0.03 ppm, JAB = 15.3 Hz, 2 H,
CH2CO2), 2.39–2.24 (m, 2 H), 2.03 (s, 3 H, CH3CO), 2.07–1.72 (m,
7 H), 1.69–1.25 (m, 8 H), 1.21–0.84 (m, 2 H), 1.08 (s, 3 H, CH3),
1.04 (s, 3 H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ = 172.0
(CO2), 170.5 (CO2), 139.8 (5-C), 121.8 (6-C), 112.9 (CN), 112.6
(CN), 73.6 (3-C), 52.1, 51.5, 51.0, 49.4, 47.4, 37.9, 36.9, 36.6, 32.4,
31.9, 31.7, 27.6, 24.3, 21.4, 20.5, 19.2 (19-C), 15.6 (18-C) ppm.
C27H36N2O4 (452.59): calcd. C 71.65, H 8.02, N 6.19; found C
71.56, H 7.97, N 6.06.
Dimethyl (2R)-2-Cyano-2,2-[(3S,17S)-3-acetoxyandrost-5-ene-17-
diyl]diacetate (14a) and Dimethyl (2S)-2-Cyano-2,2-[(3S,17S)-3-
acetoxyandrost-5-ene-17-diyl]diacetate (14b): A flexible 15 mL
PTFE tube was charged with 6 (750 mg, 1.82 mmol), 1,1-dimethox-
yethene (413 mg, 4.69 mmol), and enough benzene to fill the tube
up. The reaction mixture was set at 15 kbar and 50 °C for 64 h,
then concentrated in vacuo. The residue was dissolved in THF
(20 mL) and 1 n HCl (6 mL) was added. The reaction mixture was
stirred at room temperature for 16 h and then THF was removed
under reduced pressure. The resulting aqueous solution was ex-
tracted with CH2Cl2 and the combined organic layers were washed
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with a solution of NaHCO3, then dried (Na2SO4), filtered, and
concentrated in vacuo. Purification by column chromatography on
silica gel (heptane/EtOAc, 7:1) gave 6 (200 mg, 0.48 mmol) and a
2.7:1.0 mixture of compounds 14a and 14b (377 mg, 0.78 mmol;
43%, 58% based on recovered starting material). The assignment
of the structure to the numbers 14a and 14b was done arbitrarily.
1H NMR (300 MHz, CDCl3): δ = 5.36 (d, J = 5.1 Hz, 1 H, 6-H),
4.66–4.52 (m, 1 H, 3-H), 4.13 and 4.08 (2 s, 1 H, CHCN), 3.81
and 3.78 (2 s, 3 H, OCH3), 3.70 and 3.65 (2 s, 3 H, OCH3),
2.71 and 2.69 (2ABq, ΔδAB = 0.24 and 0.23 ppm, JAB = 15.3
and 14.1 Hz, 2 H, CH2CO2), 2.36–2.12 (m, 3 H), 2.03 (s, 3 H,
CH3CO), 2.08–1.92 (m, 2 H), 1.91–0.90 (m, 14 H), 1.03 and 1.02
(2 s, 3 H, CH3), 0.98 and 0.93 (2 s, 3 H, CH3) ppm. 13C NMR
(75 MHz, CDCl3): δ = 172.5 (CO2), 170.5 (CO2), 166.5 (CO2),
165.9 (CO2), 139.7 (5-C), 122.0 (6-C), 116.5 (CN), 73.7 (3-C), 53.2,
52.0, 51.9, 51.8, 51.6, 51.1, 50.9, 49.6, 49.5, 47.8, 47.1, 43.2, 43.0,
38.0, 36.92, 36.86, 36.6, 32.7, 32.6, 32.0, 31.9, 31.7, 31.5, 27.6, 24.3,
21.4, 20.7, 20.6, 19.2, 15.2 ppm. C28H39NO6 (485.62): calcd. C
69.25, H 8.09, N 2.88; found C 69.37, H 8.12, N 2.89.
(3S,3S,17R)-2,2-Dicyano-3-methoxy-5-oxospiro[androstane-
17,1-cyclohexan]-5-en-3-yl Acetate (15a) and (3S,3R,17R)-2,2-
Dicyano-3-methoxy-5-oxospiro[androstane-17,1-cyclohexan]-5-
en-3-yl Acetate (15b): A flexible 7.5 mL PTFE tube was charged
with 5 (500 mg, 1.32 mmol), 1-methoxy-3-[(trimethylsilyl)oxy]buta-
1,3-diene (455 mg, 2.64 mmol), and enough CH2Cl2 to fill the tube
up. The reaction mixture was set at 15 kbar and 23 °C for 17 h,
then concentrated in vacuo. The residue was dissolved in THF
(16 mL) and 1 n HCl (4 mL) was added. The reaction mixture was
stirred at room temperature for 1 h and then THF was removed
under reduced pressure. The resulting aqueous solution was ex-
tracted with CH2Cl2 and the combined organic layers were dried
(Na2SO4), filtered, and concentrated in vacuo. Purification by col-
umn chromatography on silica gel (heptane/EtOAc, 4:1) yielded a
6.0:1.0 mixture of compounds 15a and 15b (370 mg, 0.77 mmol,
59%).
Compound 15a: After recrystallization: 1H NMR (300 MHz,
CDCl3): δ = 5.34 (d, J = 4.9 Hz, 1 H, 6-H), 4.65–4.49 (m, 1 H, 3-
H), 4.23 (t, J = 4.1 Hz, 1 H, 3-H), 3.50 (s, 3 H, OCH3), 2.95 (dd,
J = 15.0, 3.9 Hz, 1 H, 4-H), 2.78 (d, J = 14.4 Hz, 1 H, 6-H), 2.69
(ddd, J = 15.0, 4.2, 1.6 Hz, 1 H, 4-H), 2.45 (dd, J = 14.4, 1.6 Hz,
1 H, 6-H), 2.37–2.22 (m, 3 H), 2.03 (s, 3 H, CH3CO), 2.03–1.92
(m, 2 H), 1.91–1.47 (m, 9 H), 1.44–1.27 (m, 3 H), 1.23 (s, 3 H, 18-
CH3), 1.19–1.05 (m, 1 H), 1.04 (s, 3 H, 19-CH3), 1.00–0.88 (m, 1
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 203.5 (5-C), 170.1
(CO2), 139.5 (5-C), 121.7 (6-C), 114.8 (CN), 114.1 (CN), 83.2 (3-
C), 73.6 (3-C), 59.4, 56.1, 50.6, 49.4, 48.8, 46.3, 44.0, 41.7, 38.1,
37.0, 36.7, 32.7, 32.6, 32.3, 32.0, 27.8, 24.5, 21.6, 20.8, 19.4 (19-C),
15.9 (18-C) ppm. C29H38N2O4 (478.63): calcd. C 72.77, H 8.00, N
5.85; found C 72.55, H 7.90, N 5.67. MS (EI+): m/z (%) = 418
(100) [M – AcOH]+, 386 (13) [M – MeOH – AcOH]+.
Methyl (2S,3S,3S,17R)-3-Acetoxy-2-cyano-3-methoxy-5-oxospi-
ro[androstane-17,1-cyclohexan]-5-ene-2-carboxylate (16a) and
Methyl (2S,3S,3R,17R)-3-Acetoxy-2-cyano-3-methoxy-5-oxo-
spiro[androstane-17,1-cyclohexan]-5-ene-2-carboxylate (16b): A
flexible 15 mL PTFE tube was charged with 6 (2.00 g, 4.86 mmol),
1-methoxy-3-[( tr imethyls ilyl)oxy]buta-1,3-diene (1.80 g,
10.46 mmol), and enough CH2Cl2 to fill the tube up. The reaction
mixture was set at 15 kbar and 50 °C for 64 h, then concentrated
in vacuo. The residue was dissolved in THF (30 mL) and 1 n HCl
(7 mL) was added. The reaction mixture was stirred at room tem-
perature for 1.5 h and then THF was removed under reduced pres-
sure. The resulting aqueous solution was extracted with CH2Cl2,
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then the combined organic layers were dried (Na2SO4), filtered, and
concentrated in vacuo. Purification by column chromatography on
silica gel (heptane/EtOAc, 4:10:1) gave 16a (2.03 g, 3.96 mmol,
82%) and 16b (282 mg, 0.55 mmol, 11%).
Compound 16a: M.p. 243–248 °C (iPr2O/MeOH, 1:1). 1H NMR
(300 MHz, CDCl3): δ = 5.36 (d, J = 5.1 Hz, 1 H, 6-H), 4.66–4.53
(m, 1 H, 3-H), 4.12 (t, J = 6.4 Hz, 1 H, 3-H), 3.84 (s, 3 H, OCH3),
3.42 (s, 3 H, OCH3), 3.03–2.73 (m, 4 H), 2.39–2.23 (m, 3 H), 2.03
(s, 3 H, CH3CO), 2.03–1.91 (m, 1 H), 1.91–1.46 (m, 9 H), 1.43–
1.24 (m, 4 H), 1.14 (s, 3 H, CH3), 1.18–1.05 (m, 1 H), 1.03 (s, 3 H,
CH3), 0.99–0.88 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ =
206.9 (5-C), 170.4 (CO2), 166.7 (CO2), 139.6 (5-C), 122.0 (6-C),
119.1 (CN), 80.2 (3-C), 73.7 (3-C), 58.6, 55.1, 53.9, 53.6, 51.2,
49.3, 48.6, 48.0, 42.3, 38.0, 36.9, 36.6, 33.8, 32.8, 32.04, 31.95, 27.6,
24.4, 21.4, 20.7, 19.2 (19-C), 15.7 (18-C) ppm. C30H41NO6 (511.66):
calcd. C 70.42, H 8.08, N 2.74; found C 70.24, H 7.89, N 2.87.
Compound 16b: 1H NMR (300 MHz, CDCl3): δ = 5.36 (d, J =
5.1 Hz, 1 H, 6-H), 4.65–4.53 (m, 1 H, 3-H), 3.87 (dd, J = 11.9,
5.0 Hz, 1 H, 3-H), 3.84 (s, 3 H, OCH3), 3.31 (s, 3 H, OCH3), 2.98–
2.76 (m, 3 H), 2.72 (dd, J = 13.9, 12.2 Hz, 1 H, 4-H), 2.45–2.10
(m, 4 H), 2.04 (s, 3 H, CH3CO), 2.03–1.77 (m, 3 H), 1.75–1.07
(m, 11 H), 1.02 (s, 3 H, CH3), 0.91–0.87 (m, 1 H), 0.90 (s, 3 H,
CH3) ppm.
(3S,17R)-6-Cyanospiro[androstane-17,1-cyclohexane]-3,5,5-tri-
ene-3,3-diyl Diacetate (17): Compound 16a (500 mg, 0.98 mmol)
was added to a methanolic LiOMe solution [Li (41 mg, 5.90 mmol)
in MeOH (50 mL)]. The resulting reaction mixture was stirred at
room temperature for 4 h, then 1 n HCl (12 mL) was added and
the volume of the mixture was reduced to one-sixth of its initial
value. The resulting aqueous solution was extracted with CH2Cl2
and the combined organic layers were dried (Na2SO4), filtered, and
concentrated in vacuo. The resulting residue was dissolved in Ac2O
(30 mL) and pyridine (8 drops) was added. The reaction mixture
was stirred at 60 °C for 6 h, then the solvent was evaporated to
dryness under high vacuum. Purification by column chromatog-
raphy on silica gel (heptane/EtOAc, 8:1) gave 17 (340 mg,
0.73 mmol, 75%), m.p. 175–177 °C (from heptane). 1H NMR
(300 MHz, CDCl3): δ = 6.80 (d, J = 6.0 Hz, 1 H, 5-H), 5.80 (dd,
J = 6.0, 2.8 Hz, 1 H, 4-H), 5.38–5.35 (m, 1 H, 6-H), 4.65–4.52 (m,
1 H, 3-H), 2.65 (dd, J = 17.9, 2.8 Hz, 1 H, 2-H), 2.63–2.54 (m, 1
H), 2.52 (d, J = 17.9 Hz, 1 H, 2-H), 2.36–2.25 (m, 2 H), 2.20 (s, 3
H, CH3CO), 2.03 (s, 3 H, CH3CO), 2.09–1.97 (m, 1 H), 1.91–1.80
(m, 2 H), 1.78–1.06 (m, 12 H), 1.01 (s, 3 H, 19-CH3), 1.02–0.92 (m,
1 H), 0.86 (s, 3 H, 18-CH3) ppm. 13C NMR (75 MHz, CDCl3): δ
= 170.6 (CO2), 167.8 (CO2), 154.6 (3-C), 139.7 (5-C and 5-C),
122.1 (6-C), 120.3 (CN), 113.0 (6-C), 109.0 (4-C), 73.8 (3-C), 49.7,
49.6, 48.9, 38.1, 38.0, 37.7, 37.0, 36.6, 34.0, 32.1, 32.0, 27.7, 24.4,
21.4, 21.3, 20.7, 19.2 (19-C), 14.7 (18-C) ppm. C29H37NO4 (463.62):
calcd. C 75.13, H 8.04, N 3.02; found C 74.96, H 8.00, N 3.06.
(3S,17R)-3-Hydroxy-5-oxospiro[androstane-17,1-cyclohexane]-
2,5-diene-2-carbonitrile (18): Compound 16a (300 mg, 0.59 mmol)
was added to a methanolic LiOMe solution [Li (27 mg, 3.89 mmol)
in MeOH (35 mL)]. The resulting reaction mixture was stirred at
room temperature for 4 h, then 1 n HCl (7 mL) was added and the
volume of the mixture was reduced to one-sixth of its initial value.
The resulting aqueous solution was extracted with CH2Cl2, and the
combined organic layers were dried (Na2SO4), filtered, and concen-
trated in vacuo. Purification by column chromatography on silica
gel (heptane/EtOAc, 3:2) gave 18 (175 mg, 0.46 mmol, 78%), m.p.
265–268 °C. 1H NMR (300 MHz, CDCl3): δ = 6.85 (t, J = 4.0 Hz,
1 H, 3-H), 5.35–5.31 (m, 1 H, 6-H), 3.57–3.45 (m, 1 H, 3-H), 3.02
(d, J = 4.0 Hz, 2 H, 4-CH2), 2.94 (d, J = 16.3 Hz, 1 H, 6-H),
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2.65–2.54 (m, 1 H), 2.35–2.19 (m, 2 H), 2.13 (d, J = 16.3 Hz, 1 H,
6-H), 2.08–1.96 (m, 1 H), 1.88–1.75 (m, 3 H), 1.69–1.35 (m, 9 H),
1.29–1.20 (m, 2 H), 1.11–1.02 (m, 1 H), 0.99 (s, 3 H, CH3), 0.93 (s,
3 H, CH3), 0.99–0.86 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 206.7 (5-C), 142.0 (3-C), 140.7 (5-C), 121.8, 121.1 (6-C), 119.0,
71.6 (3-C), 51.8, 50.5, 50.1, 49.4, 42.1, 37.2, 36.6, 32.7, 32.3, 32.0,
31.5, 24.8, 20.5, 19.3 (19-C), 16.1 (18-C) ppm. C25H33NO2 (379.54):
calcd. C 79.11, H 8.76, N 3.69; found C 79.00, H 8.93, N 3.74.
(2R,3S,17S)-3-Hydroxy-5-oxospiro[androstane-17,1-cyclohexan]-
5-ene-2-carbonitrile (19): Compound 16a (300 mg, 0.59 mmol) was
added to a methanolic LiOMe solution [Li (25 mg, 3.60 mmol) in
MeOH (30 mL)]. The resulting reaction mixture was stirred at
room temperature for 18 h, then 1 n HCl (6 mL) was added and
the volume of the mixture was reduced to one-sixth of its initial
value. The resulting aqueous solution was extracted with CH2Cl2
and the combined organic layers were dried (Na2SO4), filtered, and
concentrated in vacuo. The residue was dissolved in EtOAc/MeOH
(1:1, 80 mL) and the tip of a spatula of Pd/C (10 wt.-%) was added.
The mixture was stirred at room temperature for 3 h under a hydro-
gen atmosphere (1 atm). The reaction was filtered and the solvent
was removed under reduced pressure. Purification by column
chromatography on silica gel (heptane/EtOAc, 3:2) gave 19
(199 mg, 0.52 mmol, 89%). 1H NMR (300 MHz, CDCl3): δ = 5.35–
5.31 (m, 1 H, 6-H), 3.58–3.45 (m, 1 H, 3-H), 2.91 (br. s, 1 H, OH),
2.74–2.59 (m, 2 H), 2.43–2.15 (m, 5 H), 2.09 (dt, J = 12.2, 3.3 Hz,
1 H), 2.04–1.78 (m, 4 H), 1.77–1.00 (m, 13 H), 1.02 (s, 3 H, CH3),
0.98–0.86 (m, 1 H), 0.94 (s, 3 H, CH3) ppm. 13C NMR (75 MHz,
CDCl3): δ = 209.7 (5-C), 140.9 (5-C), 121.0, 120.5, 71.5 (3-C), 52.6,
51.2, 49.6, 45.8, 45.7, 42.1, 37.5, 37.1, 36.4, 32.9, 32.4, 31.9, 31.5,
26.6, 24.1, 20.6, 19.33, 19.28, 14.81, 14.76 ppm. C25H35NO2
(381.56): calcd. C 78.70, H 9.25, N 3.67; found C 78.65, H 9.38, N
3.65, m.p. 245–249 °C. FTIR (neat): ν˜ = 3460, 2946, 2229, 1709,
1437.
(2R,3S,17S)-2-(Acetamidomethyl)-5-oxospiro[androstane-17,1-cy-
clohexan]-5-en-3-yl Acetate (20): A solution of H2SO4/MeOH (1:20,
300 μL) was added to a solution of 19 (124 mg, 0.32 mmol) and
HC(OMe)3 (2 mL) in MeOH (18 mL). The reaction mixture was
stirred and heated to reflux for 15 min, then the solution was neu-
tralized with 1 m NaOH and the volume of the mixture was reduced
to one-third of its initial value. The resulting aqueous solution was
extracted with CH2Cl2 and the combined organic layers were dried
(Na2SO4), filtered, and concentrated in vacuo. The residue was dis-
solved in anhydrous THF (20 mL) and LiAlH4 (67 mg, 1.76 mmol)
was added portionwise. The resulting reaction mixture was stirred
and heated to reflux for 16 h, then 0.5 n NaOH (to pH 10) was
added and THF was removed under reduced pressure. The re-
sulting aqueous solution was extracted with CH2Cl2 and the com-
bined organic layers were dried (Na2SO4), filtered, and concen-
trated in vacuo. The resulting residue was dissolved in Ac2O (6 mL)
and pyridine (2 drops) was added. The new mixture was stirred at
60 °C for 16 h, then cooled to room temperature and the solvent
was evaporated to dryness under high vacuum. The residue was
dissolved in THF (5 mL) and 1 n HCl (4 mL) was added. The sol-
vent was removed after stirring the solution at room temperature
for 16 h and the resulting residue was dissolved in CH2Cl2 and the
solution was dried (Na2SO4), filtered, and concentrated in vacuo.
Purification by column chromatography on silica gel (EtOAc) gave
20 (51 mg, 0.11 mmol, 34 %), m.p. 284–289 °C. 1H NMR
(400 MHz, CDCl3): δ = 5.66 (br. s, 1 H, NH), 5.35 (d, J = 4.7 Hz,
1 H, 6-H), 4.64–4.52 (m, 1 H, 3-H), 3.66–3.53 (m, 2 H, CH2N),
2.54 (dt, J = 6.7, 14.6 Hz, 1 H, 4-H), 2.39 (d, J = 13.8 Hz, 1 H,
6-H), 2.35–2.24 (m, 2 H, 4-H2), 2.24–2.13 (m, 2 H), 2.03 (s, 3 H,
CH3CO2), 2.02 (s, 3 H, CH3CON), 1.98–1.88 (m, 3 H), 1.88–1.78
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(m, 2 H), 1.78–1.60 (m, 3 H), 1.60–1.42 (m, 7 H), 1.40–1.26 (m, 2
H), 1.25–1.05 (m, 2 H), 1.01 (s, 3 H, CH3, 19-H3), 0.94 (s, 3 H,
CH3, 18-H3), 0.95–0.84 (m, 1 H, 9-H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 213.0 (5-C), 170.6 (CO2), 170.4 (CON), 139.7 (5-C),
122.5 (6-C), 74.0 (3-C), 53.4 (17-C), 51.7 (14-C), 49.7 (9-C), 45.6
(13-C), 44.9 (6-C), 41.6 (2-C), 38.1 (4-C), 37.4 (CH2N), 37.0 (1-
C), 36.8 (4-C), 36.7 (10-C), 35.5 (16-C), 34.0 (12-C), 32.5 (8-C),
32.1 (7-C), 27.8 (2-C), 24.6 (15-C), 24.1 (3-C), 23.4 (CH3CON),
21.6 (CH3CO2), 20.9 (11-C), 19.4 (19-C), 13.9 (18-C) ppm.
C29H43NO4 (469.66): calcd. C 74.16, H 9.23, N 2.98; found C
74.00, H 9.38, N 3.01.
Supporting Information (see footnote on the first page of this arti-
cle): Copies of the 1H and 13C NMR spectra for compounds 5, 6,
9, 10a,b, 11, 13, 14a,b, 15a,b, 16a, 17–20 are available. Copies of
the 1H NMR spectra for compounds 12 and 16b are also provided.
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